{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T22:02:01Z","timestamp":1790892121048,"version":"4.1.0"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2023,4,1]]},"abstract":"<jats:sec><jats:title>Importance<\/jats:title><jats:p>Gout is common in patients with heart failure (HF), and sodium-glucose cotransporter 2 inhibitors, a foundational treatment for HF, reduce uric acid levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To examine the reported prevalence of gout at baseline, the association between gout and clinical outcomes, and the effect of dapagliflozin in patients with and without gout and the introduction of new uric acid\u2013lowering therapy and colchicine.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>This post hoc analysis used data from 2 phase 3 randomized clinical trials conducted in 26 countries, DAPA-HF (left ventricular ejection fraction [LVEF] \u226440%) and DELIVER (LVEF &amp;amp;gt;40%). Patients with New York Heart Association functional class II through IV and elevated levels of N-terminal pro\u2013B-type natriuretic peptide were eligible. Data were analyzed between September 2022 and December 2022.<\/jats:p><\/jats:sec><jats:sec><jats:title>Intervention<\/jats:title><jats:p>Addition of once-daily 10 mg of dapagliflozin or placebo to guideline-recommended therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>The primary outcome was the composite of worsening HF or cardiovascular death.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 11\u202f005 patients for whom gout history was available, 1117 patients (10.1%) had a history of gout. The prevalence of gout was 10.3% (488 of 4747 patients) and 10.1% (629 of 6258 patients) in those with an LVEF up to 40% and greater than 40%, respectively. Patients with gout were more often men (897 of 1117 [80.3%]) than those without (6252 of 9888 [63.2%]). The mean (SD) age was similar between groups, 69.6 (9.8) years for patients with gout and 69.3 (10.6) years for those without. Patients with a history of gout had a higher body mass index, more comorbidity, and lower estimated glomerular filtration rate and were more often treated with a loop diuretic. The primary outcome occurred at a rate of 14.7 per 100 person-years (95% CI, 13.0-16.5) in participants with gout compared with 10.5 per 100 person-years (95% CI, 10.1-11.0) in those without (adjusted hazard ratio [HR], 1.15; 95% CI, 1.01-1.31). A history of gout was also associated with a higher risk of the other outcomes examined. Compared with placebo, dapagliflozin reduced the risk of the primary end point to the same extent in patients with (HR, 0.84; 95% CI, 0.66-1.06) and without a history of gout (HR, 0.79; 95% CI, 0.71-0.87; <jats:italic>P<\/jats:italic>\u2009=\u2009.66 for interaction). The effect of dapagliflozin use with other outcomes was consistent in participants with and without gout. Initiation of uric acid\u2013lowering therapy (HR, 0.43; 95% CI, 0.34-0.53) and colchicine (HR, 0.54; 95% CI, 0.37-0.80) was reduced by dapagliflozin compared with placebo.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions and Relevance<\/jats:title><jats:p>This post hoc analysis of 2 trials found that gout was common in HF and associated with worse outcomes. The benefit of dapagliflozin was consistent in patients with and without gout. Dapagliflozin reduced the initiation of new treatments for hyperuricemia and gout.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial Registration<\/jats:title><jats:p>ClinicalTrials.gov Identifiers: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03036124\">NCT03036124<\/jats:ext-link> and <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03619213\">NCT03619213<\/jats:ext-link><\/jats:p><\/jats:sec>","DOI":"10.1001\/jamacardio.2022.5608","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T16:01:36Z","timestamp":1677081696000},"page":"386","source":"Crossref","is-referenced-by-count":46,"title":["Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid\u2013Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout"],"prefix":"10.1001","volume":"8","author":[{"given":"Jawad H.","family":"Butt","sequence":"first","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"},{"name":"Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran F.","family":"Docherty","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian L.","family":"Claggett","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akshay S.","family":"Desai","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Petersson","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Langkilde","sequence":"additional","affiliation":[{"name":"Late-Stage Development, Cardiovascular, Renal, and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[{"name":"Erasmus Medical Center, Rotterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian F.","family":"Hernandez","sequence":"additional","affiliation":[{"name":"Duke University Medical Center, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio E.","family":"Inzucchi","sequence":"additional","affiliation":[{"name":"Yale School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail N.","family":"Kosiborod","sequence":"additional","affiliation":[{"name":"Saint Luke\u2019s Mid America Heart Institute, Kansas City, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"K\u00f8ber","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Rigshospitalet Copenhagen University Hospital, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn S. P.","family":"Lam","sequence":"additional","affiliation":[{"name":"National Heart Centre Singapore & Duke-National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe A.","family":"Martinez","sequence":"additional","affiliation":[{"name":"University of Cordoba, Cordoba, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Ponikowski","sequence":"additional","affiliation":[{"name":"Center for Heart Diseases, University Hospital, Wroclaw Medical University, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc S.","family":"Sabatine","sequence":"additional","affiliation":[{"name":"TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women\u2019s Hospital, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjiv J.","family":"Shah","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muthiah","family":"Vaduganathan","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott D.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital, Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J. V.","family":"McMurray","sequence":"additional","affiliation":[{"name":"British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"1","key":"hbr220014r1","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1038\/s41598-022-06618-5","article-title":"The spectrum of comorbidities at the initial diagnosis of heart failure: a case control study.","volume":"12","author":"Loosen","year":"2022","journal-title":"Sci Rep"},{"issue":"9","key":"hbr220014r2","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1007\/s00392-019-01430-0","article-title":"Non-cardiac comorbidities and mortality in patients with heart failure with reduced vs. preserved ejection fraction: a study using the Swedish Heart Failure Registry.","volume":"108","author":"Ergatoudes","year":"2019","journal-title":"Clin Res Cardiol"},{"key":"hbr220014r3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.amjcard.2020.04.026","article-title":"Comparison of characteristics and outcomes of patients with heart failure with preserved ejection fraction with versus without hyperuricemia or gout.","volume":"127","author":"Carnicelli","year":"2020","journal-title":"Am J Cardiol"},{"issue":"15","key":"hbr220014r4","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1001\/archinternmed.2010.198","article-title":"Gout, allopurinol use, and heart failure outcomes.","volume":"170","author":"Thanassoulis","year":"2010","journal-title":"Arch Intern Med"},{"key":"hbr220014r5","doi-asserted-by":"publisher","DOI":"10.1177\/1759720X221102853","article-title":"Gout increases length of stay in patients hospitalized for heart failure exacerbation.","volume":"14","author":"DeMizio","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"10287","key":"hbr220014r6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","article-title":"Gout.","volume":"397","author":"Dalbeth","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"hbr220014r7","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S2665-9913(20)30221-6","article-title":"Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout.","volume":"3","author":"Hansildaar","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"hbr220014r8","doi-asserted-by":"publisher","first-page":"1916","DOI":"10.1002\/art.v72.11","article-title":"Prevalence, incidence, and years lived with disability due to gout and its attributable risk factors for 195 countries and territories 1990-2017: a systematic analysis of the Global Burden of Disease Study 2017.","volume":"72","author":"Safiri","year":"2020","journal-title":"Arthritis Rheumatol"},{"issue":"36","key":"hbr220014r9","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial.","volume":"43","author":"Doehner","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"hbr220014r10","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/ejhf.v24.6","article-title":"Dapagliflozin reduces uric acid concentration, an independent predictor of adverse outcomes in DAPA-HF.","volume":"24","author":"McDowell","year":"2022","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"hbr220014r11","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1111\/dom.v24.2","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.","volume":"24","author":"Hu","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"21","key":"hbr220014r12","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"hbr220014r13","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction.","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"hbr220014r14","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1093\/rheumatology\/kes091","article-title":"Furosemide increases plasma oxypurinol without lowering serum urate\u2013a complex drug interaction: implications for clinical practice.","volume":"51","author":"Stamp","year":"2012","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"hbr220014r15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13075-018-1612-1","article-title":"Obesity, hypertension and diuretic use as risk factors for incident gout: a systematic review and meta-analysis of cohort studies.","volume":"20","author":"Evans","year":"2018","journal-title":"Arthritis Res Ther"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2801474\/jamacardiology_butt_2023_br_220014_1681233056.98304.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,12]],"date-time":"2023-04-12T15:10:19Z","timestamp":1681312219000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2801474"}},"subtitle":["A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER"],"short-title":[],"issued":{"date-parts":[[2023,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2022.5608","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,1]]}}}